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Abstract
Background: HIV pre-exposure prophylaxis (PrEP) is highly effective for prevention of HIV acquisition, but requires
HIV testing at regular intervals. Female sex workers (FSWs) are a priority population for HIV prevention interventions
in many settings, but face barriers to accessing healthcare. Here, we assessed the acceptability of HIV self-testing for
regular HIV testing during PrEP implementation among FSWs participating in a randomized controlled trial of HIV
self-testing delivery models.
Methods: We used data from two HIV self-testing randomized controlled trials with identical protocols in Zambia and
in Uganda. From September–October 2016, participants were randomized in groups to: (1) direct delivery of an HIV
self-test, (2) delivery of a coupon, exchangeable for an HIV self-test at nearby health clinics, or (3) standard HIV testing
services. Participants completed assessments at baseline and 4 weeks. Participants reporting their last HIV test was
negative were asked about their interest in various PrEP modalities and their HIV testing preferences. We used mixed
effects logistic regression models to measure differences in outcomes across randomization arms at four weeks.
Results: At 4 weeks, 633 participants in Zambia and 749 participants in Uganda reported testing negative at their last
HIV test. The majority of participants in both studies were “very interested” in daily oral PrEP (91% Zambia; 66%
Uganda) and preferred HIV self-testing to standard testing services while on PrEP (87% Zambia; 82% Uganda).
Participants in the HIV self-testing intervention arms more often reported preference for HIV self-testing compared to
standard testing services to support PrEP in both Zambia (P = 0.002) and Uganda (P < 0.001).
Conclusion: PrEP implementation programs for FSW could consider inclusion of HIV self-testing to reduce the clinic-
based HIV testing burden.
Trial registration: ClinicalTrials.gov NCT02827240 and NCT02846402.
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Background
HIV pre-exposure prophylaxis (PrEP) is highly efficacious
for the prevention of HIV acquisition in men who have
sex with men [1] and heterosexual serodiscordant couples
[2, 3]. Although few HIV seroconversions have been docu-
mented in the context of PrEP implementation programs
in the United States [4–7], there is concern related to the
development of resistance for individuals who acquire
HIV while taking PrEP [7]. Routine HIV testing is there-
fore a core component of patient management in PrEP
programs. The World Health Organization [8] and the
Centers for Disease Control and Prevention [9] recom-
mend quarterly HIV testing for all individuals taking PrEP.
However, frequent HIV testing can be burdensome to
some PrEP patients, particularly for those who face logis-
tical barriers to accessing healthcare [10].
HIV self-testing allows individuals to test for HIV at the
time and place of their choosing, and may reduce some
barriers to accessing regular HIV testing. In the context of
PrEP implementation programs, HIV self-testing might be
a useful complement to clinic-based testing [11]. For ex-
ample, if the sensitivity and specificity of HIV self-testing
is adequate for people taking PrEP [12], HIV self-testing
could be used to screen for HIV instead of clinic visits for
some time points. HIV self-testing has generally been
shown to be acceptable [13, 14] and has been imple-
mented in diverse populations of users [15].
Female sex workers (FSW) in Sub-Saharan Africa are
disproportionately affected by the HIV epidemic [16]. PrEP
has the potential to substantially alter the course of the HIV
epidemic among FSW, particularly as a user-controlled pre-
vention intervention that does not require negotiation with
a partner, such as male condom use [17]. FSW often receive
a higher price for engaging in condomless sex, and thus may
be economically disincentivized from using male condoms
in particular [18]. PrEP may therefore be a beneficial tool for
FSW in some contexts [19]. A demonstration project of
PrEP integration into routine care for FSW in South Africa
demonstrated good uptake but suboptimal retention in PrEP
care [20]. Barriers to accessing routine HIV testing exist for
many populations of FSW, including logistical barriers such
as timing of clinic hours and interpersonal barriers such as
anticipated stigma from healthcare workers [21–24],
which may contribute to poor retention in PrEP care.
Here, we report PrEP acceptability among FSW par-
ticipating in two trials of oral HIV self-testing delivery
models in Zambia [25] and Uganda [26], and the accept-
ability of HIV self-testing in the context of PrEP use.
Methods
Participants and procedures
We conducted two separate three-arm cluster randomized
trials of HIV self-testing delivery models for FSWs in three
Zambian transit towns (ClinicalTrials.gov NCT02827240)
[25] and urban Uganda (ClinicalTrials.gov NCT02846402)
[26]. The two trials followed identical protocols and mea-
sured identical outcomes at each time point [27]. The
present analysis is a pre-specified secondary analysis from
each parent trial.
Trained peer educators each recruited 6 participants in
Zambia and 8 in Uganda. In Zambia, participants were re-
cruited in Livingstone, Kapiri Mposhi, and Chirundu, all
transit towns. In Uganda, participants were recruited in
Kampala, the capital city. In each country, individuals
were eligible for participation if they were at least 18 years
of age, reported exchanging sex for money or goods at
least once in the previous month, self-reported an HIV
negative status and no recent (< 3 months) HIV test or an
unknown HIV serostatus, and were permanent residence
in their town/city of recruitment.
All participants completed four peer educator visits at
weeks 0, 2, 6, and 10, and three study visits at baseline
prior to randomization and 4 and 16 weeks after the first
peer educator visit. We restricted our analysis to partici-
pants who self-reported that the results of their most re-
cent HIV test were negative at the 4-week study visit.
PrEP-related outcomes were only measured at the
4-week study visit, and thus no 16-week data were in-
cluded in this analysis.
Randomization
Participants were randomized in groups of one peer edu-
cator and 6 participants in Zambia and 8 participants in
Uganda. Groups were randomized in a 1:1:1 fashion to
one of three randomization arms: 1) direct distribution
of the HIV self-test kit from the peer educator to the
participant (direct delivery), 2) distribution of a coupon
from the peer educator to the participant that could be
used to collect the HIV self-test from an existing health
facility (coupon delivery), or 3) referral from the peer
educator to existing and free of charge standard HIV
testing facilities (standard of care). The randomization
list was generated in R (Version 3.3.1, The R Foundation
for Statistical Computing, Vienna, Austria) in random
blocks of size 3, 6, and 9. A separate randomization list
was generated for the Zambia and Uganda studies. In
both countries, the randomized study assignments were
placed in opaque envelopes that were opened by a peer
educator and a study staff member once each peer edu-
cator group enrolled its target number of participants.
Interventions
All participants completed four peer educator visits, at
weeks 0, 2, 6, and 10. At baseline, the peer educator visit
was done in a group setting and consisted of HIV pre-
vention counseling, distribution of male condoms, and
discussion of where participants could go for HIV test-
ing. In the HIV self-testing arms, participants were
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additionally given either an HIV self-test kit (direct deliv-
ery arm) or coupon that could be used for collection of an
HIV self-test at a participating pharmacy or health clinic
(coupon delivery). We used the OraQuick Rapid HIV-1/2
Antibody Test (OraSure Technologies, Bethlehem, PA),
which has been shown to have a sensitivity of 98.7% and
specificity of 99.8% in Zambia under field conditions
[28]. Subsequent peer educator visits were one-on-one,
and consisted of screening for adverse events, distribution
of male condoms, and additional discussion related to
HIV testing. Participants in the HIV self-testing arms were
also able to ask their peer educator if they needed any help
with HIV self-testing. At the fourth peer educator visit
(week 10), participants in the HIV self-testing arms re-
ceived a second HIV self-test or coupon for collection of
an HIV self-test at a health clinic.
Measures
Participants completed three surveys using computer-assisted
personal interview with a trained research assistant. Inter-
views occurred at baseline prior to randomization and weeks
4 and 16 following the first peer educator visit.
Demographic characteristics
At baseline, participants were asked their age, literacy (if
they could read and write), if they owned a mobile phone,
monthly income (Kwacha in Zambia or Ugandan Shillings
in Uganda), and if they had a primary partner (e.g., hus-
band or boyfriend who is not a client). Participants were
also asked the age at which they began working in sex
work. The number of years participants engaged in sex
work was calculated as the difference in their current age
and the age at which they reported starting working in sex
work. Participants were additionally asked to report the
number of clients they had on an average working night,
and how many of these they used a condom (male or fe-
male) with on average. Participants were categorized as in-
consistently using condoms (male or female) with clients
if the number of clients with whom they used a condom
(male or female) on an average night was less than their
average number of clients per night. Finally, participants
were asked to estimate how likely it was, on a 10-point
ladder scale, that they would acquire HIV in the next year.
PrEP acceptability
At the 4-week visit, research assistants read a brief script
to participants that introduced daily oral PrEP. The
script described daily oral PrEP as a new method for
preventing HIV for people who do not have HIV but are
at risk of getting it. Participants were told by the re-
search assistant that PrEP has been shown to reduce the
risk of HIV infection when taken consistently. Partici-
pants were asked how interested they were in taking
daily oral PrEP, and their responses were categorized
either as “very interested” or less. Injectable PrEP, PrEP
in the form of a vaginal microbicide, and a vaginal ring
were then introduced to participants as forms of PrEP
that were being studied. Injectable PrEP was described
as a shot that is given every 3 months. Vaginal microbi-
cides were described as gels or lubricants that were
inserted into the participant’s vagina. Vaginal rings were
described as rings that are inserted into the vagina that
lasts for one month. Participants were asked how inter-
ested they were in taking each PrEP modality, interest
was again categorized as “very interested” or less.
Acceptability of HIV self-testing during PrEP use
Participants were told by the research assistant that indi-
viduals taking PrEP should be tested for HIV every
3 months. Participants were then asked if they would be
willing to test for HIV every three months. This question
did not specify which type of testing (e.g., self-test or
standard facility-based testing). Finally, participants were
asked if they would prefer standard HIV testing at a
clinic or HIV self-testing for testing while taking PrEP.
Statistical analysis
Descriptive characteristics were calculated with propor-
tions for categorical variables and medians and inter-
quartile ranges (IQR) for continuous variables. We
calculated the proportion of participants who responded
that they would be “very willing” to use each PrEP mo-
dality across all study arms. To determine whether ex-
posure to the HIV self-testing intervention led to
increased willingness to test for HIV as part of a PrEP
program or preference for HIV self-testing versus stand-
ard testing, we used mixed effects logistic regression
model with a fixed effect for study arm and a random ef-
fect for peer educator group. All analyses were con-
ducted separately for the Uganda and Zambia studies.
All P-values were two-sided and analyses were run in
Stata 14.1 (StataCorp, College Station, TX).
Results
From September–October of 2016, 965 participants en-
rolled in the Zambia trial and 960 participants enrolled
in the Uganda trial (Fig. 1). At the four-week study visit,
retention of study participants in the Zambia trial was
92% (886/965) and retention of study participants in the
Uganda trial was 96% (926/960). Of these participants,
71% (633/886) in Zambia and 81% (749/926) in Uganda
reported testing HIV-negative at their last HIV test and
were included in our study population.
Table 1 shows the demographic characteristics of partic-
ipants in our study populations at the baseline visit. Partic-
ipants in Zambia were slightly younger than participants
in Uganda. In Zambia, the mean age of study participants
was 24 years (interquartile range [IQR] 21 to 29), while in
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Uganda the median age of study participants was 28 years
(IQR 24 to 32). The majority of participants in both stud-
ies had a primary sexual partner, self-reported the ability
to read and write and owned a mobile phone. Compared
to participants in Uganda, those in Zambia tended to be
newer to sex work, had a higher prevalence of inconsistent
condom use with clients, and perceived themselves at
greater risk of acquiring HIV in the next year. There were
no statistically significant differences in demographic
characteristics at baseline across the three randomization
arms in both Zambia and Uganda.
PrEP acceptability was high among participants in both
studies. Figure 2 shows the percentage of participants that
reported being “very interested” in the different PrEP mo-
dalities. Almost all participants in Zambia and the major-
ity of participants in Uganda reported being “very
interested” in daily oral PrEP. The vast majority of partici-
pants in both settings also reported being “very interested”
in quarterly injectable PrEP. Interest in vaginally applied
PrEP was less common. Roughly half of participants in
both settings said they would be “very interested” in PrEP
as a vaginal gel, and only 40% of participants in Zambia
and 21% of participants in Uganda said they would be
“very interested” in PrEP as a vaginal ring.
Almost all participants in both study sites (99%
Zambia; 97% Uganda) reported that they would be will-
ing to test for HIV every three months while taking
PrEP. The percentage of participants that reported will-
ingness to take PrEP by randomization arm and study
site is shown in Table 2. The different HIV self-testing
delivery models did not significantly affect participants’
willingness to test for HIV every three months while on
PrEP in either Zambia (P = 0.64) or Uganda (P = 0.19).
The different HIV self-testing delivery models did,
however, significantly affect participants’ preference
for HIV self-testing over standard HIV testing services
in both Zambia and Uganda. Figure 3 shows the per-
centage of participants by randomization arm and
study site that reported a preference for HIV
self-testing or standard HIV testing services at a
clinic while taking PrEP. In both Zambia and Uganda,
the percentage of participants that reported a prefer-
ence for HIV self-testing versus standard HIV testing
services while on PrEP was greater in both the HIV
self-testing intervention arms compared to the stand-
ard of care arm, and differences in this outcomes
across randomization arms were statistically signifi-
cant both in settings (P = 0.002 Zambia; P < 0.001
Fig. 1 Flow of participants included in the study in both Zambia and Uganda
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Uganda). The majority of all participants both Zambia
(87%) and Uganda (81%), however, preferred HIV
self-testing versus standard HIV testing services while
on PrEP.
Discussion
FSW in both Zambian transit towns and urban Uganda
reported high interest in PrEP and preferred HIV
self-testing over standard HIV testing services at clinics
to test for HIV regularly (every 3 months) while on
PrEP. HIV self-testing for regular, repeat testing was ac-
ceptable among FSWs in this study, especially among
those who previously had the opportunity to self-test.
FSW who had the opportunity to self-test previously
may have preferred this approach over standard HIV
testing services because they were less intimidated by
the new testing technology and had a favorable experi-
ence HIV self-testing. These results indicate that HIV
self-testing could be used to support PrEP delivery by
moving some of the burden of HIV testing outside of
Table 1 Baseline demographic characteristics of the study sample
Direct HIVST distribution HIVST coupon distribution Standard testing
Zambia
Sample Size N = 222 N = 217 N = 194
Age (med, IQR) 24 (20 to 28) 24 (21 to 29) 24 (21 to 29)
Have a primary partner 127 (57%) 133 (61%) 121 (62%)
Can read and write 175 (79%) 176 (81%) 137 (71%)
Mobile phone ownership 185 (83%) 190 (88%) 170 (88%)
Monthly income
No income 48 (22%) 50 (23%) 45 (%)
< 250 kwachaa 21 (10%) 40 (19%) 28 (%)
251–500 kwachaa 58 (26%) 41 (19%) 42 (%)
501–1000 kwachaa 55 (25%) 57 (27%) 44 (%)
1001–1500 kwachaa 21 (10%) 15 (7%) 13 (%)
> 1500 kwachaa 17 (8%) 11 (5%) 19 (%)
Years in sex work (med, IQR) 4 (2 to 8) 5 (3 to 8) 3 (5 to 9)
Inconsistent condom use with clients 169 (77%) 152 (71%) 144 (76%)
Risk of acquiring HIV in next year, 10-point scaleb (med, IQR) 6 (5 to 8) 6 (5 to 7) 5 (4 to 7)
Uganda
Sample size N = 247 N = 240 N = 262
Age (med, IQR) 27.5 (24 to 31) 28 (24 to 31) 28 (24 to 32)
Have a primary partner 160 (67%) 141 (57%) 156 (60%)
Can read and write 209 (87.1) 209 (84.6) 228 (88.0)
Mobile phone ownership 235 (98%) 233 (94%) 249 (95%)
Monthly income
No income 2 (1%) 0 (0%) 0 (0%)
< 250 UGXc 50 (21%) 56 (23%) 41 (16%)
251–500 UGXc 69 (29%) 80 (33%) 106 (41%)
501–1000 UGXc 88 (37%) 83 (34%) 90 (35%)
1001–1500 UGXc 27 (11%) 19 (8%) 22 (8%)
> 1500 UGXc 4 (2%) 5 (2%) 2 (1%)
Years in sex work (med, IQR) 5 (3 to 8) 4 (3 to 8) 5 (2 to 8)
Inconsistent condom use with clients 104 (44%) 101 (41%) 104 (40%)
Risk of acquiring HIV in next year, 10-point scaleb (med, IQR) 4 (2 to 6) 5 (3 to 6) 4 (2 to 5)
aExchange rate: 1 USD = 9.2 Zambian Kwacha (September 2016)
bParticipants were asked to indicated how likely it is that they will contract HIV in the next year using a 10-rung ladder scale. Larger scores indicated a greater
likelihood of getting HIV
cExchange rate: 1 USD = 3366 Uganda shilling (UGX) (October 2016)
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health clinics, preventing stigma and discrimination of
FSW from healthcare providers and maintaining the
confidentiality of FSW taking PrEP [22].
Daily oral PrEP has been shown to be acceptable [29]
and implementation to be feasible [20] among other
populations of FSWs. In the current study, acceptability
of PrEP for prevention of HIV acquisition was high
among FSWs in both Zambia and Uganda, but some
PrEP modalities were more popular than others. In both
study settings, FSWs preferred daily oral PrEP or quar-
terly injectable PrEP over PrEP in the form of a vaginal
gel or ring. This preference is likely explained by the
prevalence of various types of non-barrier contraceptive
methods available to women in these countries. A recent
study conducted among the same population of FSW in
Zambia found that the majority of FSW who used a
method of non-barrier contraception used injectable
contraception; the second most common form of
non-barrier contraception was the oral birth control pill
[30]. Less than 1 % of Zambian FSW in that study re-
ported use of the vaginal ring [30]. Lack of familiarity
with contraceptives inserted in the vagina might have
made FSW less interested in PrEP modalities that uti-
lized this strategy.
Acceptability of HIV self-testing was extremely high
across randomization arms in both Zambia and Uganda.
More than two thirds of participants in the standard of
care arm preferred HIV self-testing to standard HIV test-
ing services while taking PrEP in both settings, despite
never having had the opportunity to self-test themselves.
Willingness to test for HIV every three months was also
near universal in both settings, thus suggesting that
barriers to HIV self-testing among members of this
population are likely attributable to logistics or stigma
and discrimination from healthcare providers rather
than a lack of will. As demonstrated in the two parent
trials, HIV self-testing has the potential to help FSW
overcome some of these barriers and achieve both high
HIV testing coverage and high levels of repeat testing
[22, 26]. A recent study, however, suggests that FSW
might have difficulty interpreting HIV self-test results
[31], indicating that appropriate pre-test training and
on demand support should be considered with the im-
plementation of HIV self-testing.
This study has both strengths and limitations. We found
consistent results in two diverse populations of FSWs,
improving the generalizability of our findings. Participants
were engaged in a randomized trial of HIV self-testing, and
thus we were able to compare preferences for HIV
self-testing between women who had been randomized to
receive a self-test compared to those who did not receive a
self-test. Questions related to acceptability of HIV
self-testing were therefore not hypothetical for women who
had previously had exposure to an HIV self-test. None of
the participants in this study, however, actually used or had
access to PrEP, and thus they might not have fully under-
stood the research assistants’ explanation of this HIV pre-
vention intervention. Also, as a hypothetical scenario,
Fig. 2 Proportion of participants reporting to be “very interested” in PrEP modality in Zambia and Uganda
Table 2 Willingness to be tested for HIV every three months while taking PrEP by randomization arm
Direct HIVST distribution HIVST coupon distribution Standard testing P-value1
Zambia 217 (98.2%) 214 (98.6%) 191 (99.0%) 0.64
Uganda 232 (97.1%) 235 (94.4%) 257 (96.5%) 0.19
1Estimated using mixed effects logistic regression models with a fixed effect for study arm and a random effect for peer educator group
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participants may be more or less likely to indicate that they
would use an intervention than they would if they were ac-
tually making a decision in real life. Actual behaviors may
therefore differ from anticipated behavior. Finally, our se-
lection of study participants may have induced bias in the
effect estimates because we selected on a variable (i.e.,
HIV-negative status) that was reported after randomization.
However, PrEP is only indicated for individuals who test
negative for HIV, and participants who are living with HIV
may have substantially different responses to hypothetical
questions regarding HIV prevention. Furthermore, to in-
duce bias, the study randomization arm would have to
causally affect HIV status. It is unlikely for this to occur in
the one-month timeframe of the study.
Conclusions
In many sub-Saharan African countries, FSW are a pri-
ority population for HIV prevention interventions be-
cause of their increased risk of both HIV acquisition and
transmission [16, 32]. As more sub-Saharan African
countries, including Kenya, Uganda, and South Africa,
begin to scale PrEP nationally, understanding prefer-
ences for PrEP and interventions for ongoing engage-
ment in care is of increased importance. Here, we found
that PrEP is highly acceptable among members of this
population and that HIV self-testing is preferred over
standard HIV testing services to support regular HIV
testing while on PrEP. Previous studies have found HIV
self-testing to be effective at increasing frequent testing
among FSWs [25, 26]. Policy makers should consider
both scaling PrEP to FSW living in high prevalence areas
and using HIV self-tests to support PrEP delivery and fa-
cilitate detection of breakthrough HIV infections.
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